Adipotide

Also known as FTPP, Prohibitin-targeting peptide 1, CKGGRAKDC-GG-D(KLAKLAK)2

A preclinical pro-apoptotic peptidomimetic that homes to white-fat blood vessels and triggers their death, causing fat loss in animal studies — but with dose-limiting kidney toxicity.

Molecular weight2611.4 g/mol

Half-lifeShort — minutes to a few hours (estimated; rapid renal clearance reported in animals).

CategoryMetabolic

Typical use cases

✓ Obesity/fat-loss research✓ Targeted vascular ablation studies✓ Insulin-resistance models

Dosing guidelines

StartingPreclinical only — primate studies used ~0.43 mg/kg/day SC; there is no validated human dose.

MaintenanceNo established maintenance dose; animal studies dosed daily for ~4-week cycles.

Max (studied)Unknown/undefined in humans; higher doses worsened renal toxicity in animals, so no safe upper bound is established.

Titration

Typically flat-dosed in short cycles (e.g. ~28 days) in animal studies; no human titration scheme exists.

Reconstitution

10 mg vial: add ~2 mL bacteriostatic water (~5 mg/mL); swirl gently.

Injection sites

Subcutaneous, rotate sites (abdomen/thigh) — route used in animal research.

Storage & handling

Lyophilized: stable months cool/dark, longer frozen. Reconstituted: refrigerate (2–8 °C).

Side effects

Renal tubular toxicity (proteinuria/glucosuria) Severe · Common
Dehydration / increased urination Moderate · Common
Injection-site reaction Mild · Uncommon
Electrolyte disturbance Moderate · Uncommon

Research summary

Adipotide (FTPP) is a chimeric peptide joining a prohibitin/annexin-A2 homing domain (CKGGRAKDC) to a pro-apoptotic D-peptide that disrupts mitochondrial membranes in the endothelium of white adipose tissue, pruning the fat's blood supply. In a 2011 obese-rhesus-monkey study animals lost roughly 10% body weight over ~28 days with improved insulin sensitivity; earlier work showed similar effects in obese mice. Evidence is entirely preclinical (mouse and non-human primate) — there are no completed human efficacy trials, and studies documented dose-dependent renal tubular changes (proteinuria, glucosuria) that flag a narrow therapeutic window. Educational only — not medical advice.

Key references

Kolonin et al., Nature Medicine (2004) — adipose vasculature-targeting peptide in obese mice
Barnhart et al., Science Translational Medicine (2011) — adipotide causes weight loss in obese monkeys

Related compounds

Semaglutide → Tirzepatide → 5-Amino-1MQ →

Where to buy

🛍 Core Peptides Third-party tested ↗

These are affiliate links. Purchasing through them helps support DoseForge at no extra cost to you.

Educational reference only — not medical advice. Dosing figures are commonly-cited ranges, not prescriptions. Consult a qualified clinician.

Track Adipotide in DoseForge

Log doses, rotate sites, watch your progress — free.

Get the app